Combined Donepezil and Selegiline Effects on Cocaine-Reinforced Behavior
NCT ID: NCT01495195
Last Updated: 2013-12-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
12 participants
INTERVENTIONAL
2012-02-29
2013-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
We have recently shown that pretreatment with certain cholinesterase inhibitors can produce large reductions in cocaine-reinforced behavior in rats (drug self-administration is decreased by more than 70% over a period of three days during which no additional cholinesterase inhibitor is administered). Because the reductions persist over a period two or more weeks, they have been described as persistent attenuation. Similar reductions have been observed after rats receive pretreatment with the cholinesterase inhibitors donepezil or tacrine, but not rivastigmine. The key difference leading to persistent attenuation may be effects of donepezil or tacrine on catecholamine neurotransmitters. Specifically, our hypothesis is that persistent attenuation is caused by a combination of 1.) Cholinesterase inhibition, which increases brain levels of acetylcholine (ACh); and 2.) Increased brain levels of dopamine and serotonin. Although well-tolerated, pretreatment with low doses of the cholinesterase inhibitor donepezil have not modified either the positive subjective effects of cocaine in humans, or cocaine use in outpatients. This may reflect the relatively low doses of donepezil administered (up to 10 mg daily). Transdermal selegiline is a well-tolerated, nonselective monoamine oxidase inhibitor that potentiates actions of dopamine and serotonin in the central nervous system.
Rationale Persistent attenuation may be achieved in humans by administering donepezil at higher doses, or in combination with a centrally-acting inhibitor of monoamine oxidase (MAO). Inhibition of MAO increases brain levels of dopamine and serotonin. If persistent attenuation can be accomplished in humans, this would lead to an important paradigm shift for substance abuse treatment, in that large reductions in cocaine-reinforced behavior could be produced without the need for continuous dosing with a medication. This scenario could remove the requirement for continued compliance with oral dosing in some patients with its associated potential for toxicity.
Specific Aims:
1. Determine whether donepezil can be safely advanced over a 17-day period to an individualized dose of up to 22.5 mg daily (or the highest dose tolerated by each participant).
2. Evaluate whether high-dose donepezil attenuates cocaine-reinforced behavior in humans.
3. Determine whether combined donepezil and selegiline produces greater reductions in cocaine-reinforced behavior than observed for donepezil alone.
Methods This is a randomized, single-blind, placebo-controlled, research-unit, single-center evaluation of the potential for oral donepezil, with or without transdermal selegiline to modify cocaine self-administration in a laboratory setting. Up to 32 non-treatment-seeking, regular cocaine users will be assigned to receive one of four treatments: 1.) Oral placebo; 2.) High-Dose Donepezil \[titrated to 22.5 mg daily\]; and 3.) Low-Dose Donepezil \[titrated to 10 mg daily\] and transdermal selegiline \[6 mg daily\]; and 4.) High-Dose Donepezil \[titrated to 22.5 mg daily\] and transdermal selegiline \[6 mg daily\]. For participants who receive donepezil, it will be advanced to either a target dose (low or high), or a lower dose that is tolerated by individual participants. To evaluate the occurrence of persistent attenuation, cocaine use will be measured over a nine-day follow-up period, through urine drug screens and the timeline-follow-back method. As noncontingent infusions of cocaine are administered, the pharmacokinetics of cocaine and donepezil will be determined.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Donepezil, high-dose
Titration of donepezil to 22.5 mg daily
High-dose donepezil
Donepezil titrated to 22.5 mg daily
Selegiline & low-dose donepezil
Low-Dose Donepezil \[titrated to 10 mg daily\] and transdermal selegiline \[6 mg daily\]
Low-dose donepezil
Donepezil titrated to 10 mg daily
Selegiline
Transdermal selegiline, 6 mg daily
Selegiline & high-dose donepezil
High-Dose Donepezil \[titrated to 22.5 mg daily\] and transdermal selegiline \[6 mg daily\]
High-dose donepezil
Donepezil titrated to 22.5 mg daily
Selegiline
Transdermal selegiline, 6 mg daily
Sugar pill
Inert pill for comparison
Placebo
microcrystalline cellulose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
High-dose donepezil
Donepezil titrated to 22.5 mg daily
Low-dose donepezil
Donepezil titrated to 10 mg daily
Selegiline
Transdermal selegiline, 6 mg daily
Placebo
microcrystalline cellulose
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least one cocaine-positive urine within 6 weeks prior to enrollment
* Has used cocaine for a duration of at least 6 months
* At least weekly cocaine use during the last 30 days
Exclusion Criteria
* Any current Axis I psychiatric disorder other than drug abuse or dependence
* Dependence on abused substances other than cocaine
* Current or past history of seizure disorder
* Heart or lung disease
21 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Drug Abuse (NIDA)
NIH
Midwest Biomedical Research Foundation
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
KENNETH GRASING
Director, Substance Abuse Research Laboratory, Kansas City VA Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kansas City VA Medical Center
Kansas City, Missouri, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Grasing K, Mathur D, Newton TF, DeSouza C. Donepezil treatment and the subjective effects of intravenous cocaine in dependent individuals. Drug Alcohol Depend. 2010 Feb 1;107(1):69-75. doi: 10.1016/j.drugalcdep.2009.09.010.
Grasing K, Yang Y, He S. Reversible and persistent decreases in cocaine self-administration after cholinesterase inhibition: different effects of donepezil and rivastigmine. Behav Pharmacol. 2011 Feb;22(1):58-70. doi: 10.1097/FBP.0b013e3283428cd8.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCT01406522B
Identifier Type: -
Identifier Source: org_study_id